News — New York, NY – Oct. 23, 2024 – The American Thoracic Society is accepting scientific abstracts and case report submissions for presentation at the ATS 2025 International Conference. Submissions on all aspects of respiratory disease, critical care medicine and sleep medicine will be considered and are due no later than 5 p.m. ET, Wednesday, Nov. 6, 2024.

The full are available online now on the

As the largest meeting of respiratory health professionals, the American Thoracic Society International Conference is a great platform to showcase research. Whether reporting on basic, behavioral, translational, or clinical science research, if accepted for presentation at ATS 2025, scientific abstracts and case reports will be shared with more than 10,000 attendees, some of whom are the most influential and respected researchers in the lung space.

In addition to sharing scientific discoveries with the research and clinical communities, presenters will have their abstracts published in the special (AJRCCM) in May 2025. AJRCCM is one of the highest ranked journals in pulmonology.

Furthermore, the international conference highlights a select number of abstracts in news releases.

Committed to engaging diverse voices and points of view, the ATS welcomes submissions from researchers worldwide.

###

About the American Thoracic Society:

Founded in 1905, the American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through multidisciplinary collaboration, education, and advocacy. Core activities of the Society’s more than 16,000 members are focused on leading scientific discoveries, advancing professional development, impacting global health, and transforming patient care. Key areas of member focus include developing clinical practice guidelines, hosting the annual Conference, publishing four , advocating for improved respiratory health globally, and developing an array of patient education and career development resources. 

Please visit our  to learn more. Join the conversation and our community on Twitter/X, Facebook, Instagram and LinkedIn.